Literature DB >> 26948252

Addition of indapamide to frusemide increases natriuresis and creatinine clearance, but not diuresis, in fluid overloaded ICU patients.

Shailesh Bihari1, Andrew W Holt2, Shivesh Prakash3, Andrew D Bersten4.   

Abstract

BACKGROUND: Fluid and sodium overload are a common problem in critically ill patients. Frusemide may result in diuresis in excess of natriuresis. The addition of indapamide may achieve a greater natriuresis, and also circumvent some of the problems associated with frusemide. The objective of this study was to examine the effect of adding indapamide to frusemide on diuresis, natriuresis, creatinine clearance and serum electrolytes.
METHODS: Fluid overloaded ICU patients were randomised to either intravenous frusemide (Group F) or intravenous frusemide and enteral indapamide (Group F + I). Comprehensive exclusion criteria were applied to address confounders. 24 hour urine was analysed for electrolytes and creatinine. Serum electrolytes were measured before and 24 hours after administration of diuretics.
RESULTS: Forty patients (20 in each group) were included in the study. The groups were similar in their baseline characteristics. Over the 24 h study period, patients in Group F + I, had a larger natriuresis (P = 0.01), chloride loss (P = 0.01) and kaliuresis (P = 0.047). Patients in Group F + I also had a greater 24 hour urinary creatinine clearance (P = 0.01). The 24 hour urine volume and fluid balance was similar between the groups. Patients in Group F had an increase in serum sodium (P = 0.04), while patients in Group F + I had a decrease in both serum chloride (P = 0.01) and peripheral oedema (P < 0.001) during the study duration.
CONCLUSION: In fluid overloaded ICU patients, addition of indapamide to frusemide led to a greater natriuresis and creatinine clearance. Such a strategy might be utilised in optimising sodium balance in ICU patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diuresis; Fluid Balance; Frusemide; Indapamide; Natriuresis; Sodium Balance

Mesh:

Substances:

Year:  2016        PMID: 26948252     DOI: 10.1016/j.jcrc.2016.01.017

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  5 in total

1.  Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation After Resuscitation-2 (RADAR-2) randomised clinical trial.

Authors:  Jonathan A Silversides; Ross McMullan; Lydia M Emerson; Ian Bradbury; Jonathan Bannard-Smith; Tamas Szakmany; John Trinder; Anthony J Rostron; Paul Johnston; Andrew J Ferguson; Andrew J Boyle; Bronagh Blackwood; John C Marshall; Daniel F McAuley
Journal:  Intensive Care Med       Date:  2021-12-16       Impact factor: 17.440

2.  Fluid management and deresuscitation practices: A survey of critical care physicians.

Authors:  Jonathan A Silversides; Daniel F McAuley; Bronagh Blackwood; Eddy Fan; Andrew J Ferguson; John C Marshall
Journal:  J Intensive Care Soc       Date:  2019-05-13

Review 3.  Recommendations for active correction of hypernatremia in volume-resuscitated shock or sepsis patients should be taken with a grain of salt: A systematic review.

Authors:  Joseph W Quinn; Kerry Sewell; Dell E Simmons
Journal:  SAGE Open Med       Date:  2018-03-21

Review 4.  Fluid-induced harm in the hospital: look beyond volume and start considering sodium. From physiology towards recommendations for daily practice in hospitalized adults.

Authors:  Niels Van Regenmortel; Lynn Moers; Thomas Langer; Ella Roelant; Tim De Weerdt; Pietro Caironi; Manu L N G Malbrain; Paul Elbers; Tim Van den Wyngaert; Philippe G Jorens
Journal:  Ann Intensive Care       Date:  2021-05-17       Impact factor: 6.925

5.  Fluid Overload Phenotypes in Critical Illness-A Machine Learning Approach.

Authors:  Anna S Messmer; Michel Moser; Patrick Zuercher; Joerg C Schefold; Martin Müller; Carmen A Pfortmueller
Journal:  J Clin Med       Date:  2022-01-11       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.